Definitive Contract 75A50124C00047
Award Date
9/30/24
Potential Completion Date
11/22/30
Potential Value
$120M
Awardee
Synedgen, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Claremont, CA 91711, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,223,612 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Ceramedix Holding, LLC, a small disadvantaged business, for the development of an anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract has a period of performance ending on June 30, 2026. The contract involves two subcontractors: the Sloan-Kettering Institute for Cancer Research, which will characterize...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...
This federal contract award to Innovation Pathways, LLC, a for-profit limited liability company, is for the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule. The $3,499,688.00 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, and has no set-aside designation. The contract work supports research and development...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...
This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to SRI International, a non-profit research and development institute. The contract, valued at $715,633.86, is for radiation/nuclear medical countermeasure (MCM) product development support services, specifically the formulation of 3,4,3-Li(1,2-HOPO). This contract is not a set-aside and is part of a...
This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures. The contract is for the development of medical countermeasures that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The...
This federal contract award to Chromologic LLC, a minority-owned small business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for the "Development of Second-Generation Probiotics as Radiation Mitigators." The $2,709,458.08 cost-plus-fixed-fee contract has a 5-year period of performance through March 2026. The contract supports research and development of advanced therapeutic approaches, including...
This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
This is a $20,000,000.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Bioaegis Therapeutics Inc. The contract is for the development of BIOAEGIS: Plasma Gelsolin (PGSN), an abundant, circulating protein that modulates inflammation and enhances host defenses against pathogens, for the treatment of Acute Respiratory Distress Syndrome. The contract has an ultimate completion date of August 31, 2027 and...